| Dr David Karl Mehne, MD | |
|
Edifcio Profecional Menonita, Suite 306, Aibonito, PR 00705 | |
| (787) 735-0333 | |
| (787) 735-0220 |
| Full Name | Dr David Karl Mehne |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 48 Years |
| Location | Edifcio Profecional Menonita, Aibonito, Puerto Rico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831290618 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 7608 (Puerto Rico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mennonite General Hospital Inc | Aibonito, PR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mennonite General Hospital Inc | 6709843964 | 71 |
News Archive
The American Society of Hematology (ASH), the world's largest organization concerned with the causes and treatment of blood disorders, today released the Blood journal app for iPhone and iPad. Blood is the official Journal of the Society and the most cited peer-reviewed publication in the field.
A new study in the American Journal of Preventive Medicine, published by Elsevier, found that motor vehicle crashes involving drivers with blood alcohol concentrations below the legal limit of 0.08 percent accounted for 15 percent of alcohol-involved crash deaths in the United States.
Antipodean Pharmaceuticals has announced it has initiated a Phase 2 clinical trial of its lead compound MitoQ (mitoquinone) to investigate the drug's efficacy to reduce liver damage in patients with raised liver enzymes associated with the Hepatitis C virus (HCV).
A novel mutation found in a mouse gene might provide new insights into the genetic roots of alcoholism in humans, according to a study led by researchers at the Ernest Gallo Clinic and Research Center and the University of California, San Francisco. The study is published August 12th in the open-access journal PLoS Genetics.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that the Marketing Authorisation Application (MAA) for Glybera(R) remains on schedule following meetings with the European Medicine Agency (EMA) concerning the Day 120 List of Questions. The company is confident that Glybera(R), a gene therapy product for lipoprotein lipase deficiency (LPLD), remains on track for a regulatory decision by mid-2011.
› Verified 4 days ago
| Entity Name | Mennonite General Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851320394 PECOS PAC ID: 6709843964 Enrollment ID: O20041220000467 |
News Archive
The American Society of Hematology (ASH), the world's largest organization concerned with the causes and treatment of blood disorders, today released the Blood journal app for iPhone and iPad. Blood is the official Journal of the Society and the most cited peer-reviewed publication in the field.
A new study in the American Journal of Preventive Medicine, published by Elsevier, found that motor vehicle crashes involving drivers with blood alcohol concentrations below the legal limit of 0.08 percent accounted for 15 percent of alcohol-involved crash deaths in the United States.
Antipodean Pharmaceuticals has announced it has initiated a Phase 2 clinical trial of its lead compound MitoQ (mitoquinone) to investigate the drug's efficacy to reduce liver damage in patients with raised liver enzymes associated with the Hepatitis C virus (HCV).
A novel mutation found in a mouse gene might provide new insights into the genetic roots of alcoholism in humans, according to a study led by researchers at the Ernest Gallo Clinic and Research Center and the University of California, San Francisco. The study is published August 12th in the open-access journal PLoS Genetics.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that the Marketing Authorisation Application (MAA) for Glybera(R) remains on schedule following meetings with the European Medicine Agency (EMA) concerning the Day 120 List of Questions. The company is confident that Glybera(R), a gene therapy product for lipoprotein lipase deficiency (LPLD), remains on track for a regulatory decision by mid-2011.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Karl Mehne, MD Edifcio Profesional Menonita, Suite 306, Aibonito, PR 00705 Ph: (787) 735-0333 | Dr David Karl Mehne, MD Edifcio Profecional Menonita, Suite 306, Aibonito, PR 00705 Ph: (787) 735-0333 |
News Archive
The American Society of Hematology (ASH), the world's largest organization concerned with the causes and treatment of blood disorders, today released the Blood journal app for iPhone and iPad. Blood is the official Journal of the Society and the most cited peer-reviewed publication in the field.
A new study in the American Journal of Preventive Medicine, published by Elsevier, found that motor vehicle crashes involving drivers with blood alcohol concentrations below the legal limit of 0.08 percent accounted for 15 percent of alcohol-involved crash deaths in the United States.
Antipodean Pharmaceuticals has announced it has initiated a Phase 2 clinical trial of its lead compound MitoQ (mitoquinone) to investigate the drug's efficacy to reduce liver damage in patients with raised liver enzymes associated with the Hepatitis C virus (HCV).
A novel mutation found in a mouse gene might provide new insights into the genetic roots of alcoholism in humans, according to a study led by researchers at the Ernest Gallo Clinic and Research Center and the University of California, San Francisco. The study is published August 12th in the open-access journal PLoS Genetics.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that the Marketing Authorisation Application (MAA) for Glybera(R) remains on schedule following meetings with the European Medicine Agency (EMA) concerning the Day 120 List of Questions. The company is confident that Glybera(R), a gene therapy product for lipoprotein lipase deficiency (LPLD), remains on track for a regulatory decision by mid-2011.
› Verified 4 days ago